US Bancorp DE Purchases 11,729 Shares of Novo Nordisk A/S (NYSE:NVO)

US Bancorp DE increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 3.0% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 405,670 shares of the company’s stock after purchasing an additional 11,729 shares during the period. US Bancorp DE’s holdings in Novo Nordisk A/S were worth $41,968,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Novo Nordisk A/S by 17.2% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 166,432 shares of the company’s stock worth $17,217,000 after buying an additional 24,479 shares during the last quarter. Balboa Wealth Partners raised its holdings in Novo Nordisk A/S by 62.7% in the 4th quarter. Balboa Wealth Partners now owns 3,731 shares of the company’s stock valued at $386,000 after acquiring an additional 1,438 shares during the period. Frazier Financial Advisors LLC acquired a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $158,000. Tidemark LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth approximately $31,000. Finally, JPL Wealth Management LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $372,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.3 %

Shares of NYSE:NVO traded up $0.47 during midday trading on Friday, reaching $136.04. The company’s stock had a trading volume of 2,845,222 shares, compared to its average volume of 4,075,833. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The firm has a 50 day moving average price of $128.21 and a two-hundred day moving average price of $116.45. The firm has a market capitalization of $610.48 billion, a price-to-earnings ratio of 46.91, a PEG ratio of 1.40 and a beta of 0.43.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.77 by $0.06. The company had revenue of $9.52 billion during the quarter, compared to the consensus estimate of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. As a group, analysts forecast that Novo Nordisk A/S will post 3.43 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on NVO shares. BMO Capital Markets began coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.